Our Recommendations
- WHO consolidated guidelines on drug-resistant tuberculosis treatment (2019)
- Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) (2018)
- WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update (2016)
- Field Guide for the Management of Drug-Resistant Tuberculosis (2018)
- Вебинар: когорный анализ в рамках программного внедрения новых режимов лечения ЛУ-ТБ (2018)
New Publications
- Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 2nd ed (2023)
- The use of next-generation sequencing for the surveillance of drug-resistant tuberculosis: an implementation manual (2023)
- Child-friendly formulations for drug-resistant tuberculosis (2022)
- WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment,update (2022)
- WHO operational handbook on tuberculosis: module 4: treatment: tuberculosis care and support (2022)
Filter
76
Featured
Recommendations
10
New Publications
15
Language
Document type
No document type
47
Guidelines
10
Manuals
6
Studies & Reports
6
Training Material
4
Online Courses
1
Videos
1
Fact sheets
1
Countries / Regions
Russia
4
Tajikistan
1
Colombia
1
Ukraine
1
El Salvador
1
Peru
1
Armenia
1
Global
1
Eastern Europe
1
India
1
Authors & Publishers
Publication Years
Category
TB
29
Policies & Guidelines HIV & TB
4
Disease Prevention & Control
2
Bacteriology
1
Public Health
1
Information, Education and Communication (IEC)
1
Studies & Reports
1
Capacity Building
1
Toolboxes
Drug resistant TB
76
Adults
11
Training
10
Detection & Diagnosis
7
Clinical Guidelines
6
Children
5
Prevention & Control
4
Laboratory
3
Research & Access
3
TB
2
Laboratory
2
Essential Medicines
2
Eastern Europe & Central Asia
2
Policies & Strategies
1
Childhood TB
1
Hepatitis
1
Communication & Training
1
IEC Materials
1
SOPs
1
Drug resistance
1
Colombia
1
Peru
1
El Salvador
1
Prices and Patents
1
Rational use of Medicine
1
HIV &TB
1
Armenia
1
TB & Prisoners
1
TB/HIV Coinfection
1
Tajikistan
1
TB
1
Данный инструмент должен использоваться для документирования клинического ведения пациентов, облегчения процесса обучения персонала на рабочем месте и обсужден...
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
Презентация на тему значимости скрининга больных с лекарственно-устойчивым туберкулезом на гепатит С. Как лучше всего лечить этих пациентов от гепатита С.
The third edition, released in 2018, has grown to include a total of 18 chapters, contributed by 20 experts and authors from many countries. The goal remains the same: to educate primary care providers on the best practices in TB diagnosis, treatment and follow-up. All articles are richly illustrate...
Целью данной презентации является предоставление рекомендаций для работников здравоохранения, которые участвуют в лечении, мониторинге, оценке, анализе и отчетн...
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ...
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
A large meta-analysis of observational studies that provided the basis for the recent makeover of global recommendations for multidrug-resistant tuberculosis (MDR-TB) treatment shows that newer and repurposed drugs produced better outcomes and fewer deaths than older treatments.
The meta-analysis...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
This training toolkit by the European Laboratory Initiative for TB, HIV and Viral Hepatitis provides a unique combination of practical guidance and expert advice on the interpretation of selected WHO-endorsed tests for drug-resistant tuberculosis (DR-TB).
The guide is organized into the major types of toxicities, the associated symp-toms, possible offending medications, and the suggested nursing assessments and interventions. Some symptoms (e.g. nausea) may be associated with a num-ber of underlying causes and may be mild, or a symptom of...
Ce guide sur la tuberculose résistante est un outil pratique destiné à aider les agents de santé à prendre en charge le malade du point de vue clinique et opérationnel en mettant l’accent sur la décision thérapeutique, la mise en œuvre et le suivi du régime court de 9 mois pour le traite...
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
